Poststroke epilepsy
Conditions
Interventions
None listed
Sponsors
Academisch Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion-criteria for the stroke patients with seizures/epilepsy: • History of seizures or epilepsy after stroke, including all patients with one or more seizures at the beginning of a stroke or thereafter, in whom a diagnosis of post-stroke seizures or epilepsy was established based on clinical grounds. • The last seizure is > 2 weeks ago at time of measurement (to avoid possible interference with cognitive function). • The diagnosis of post-stroke epilepsy was made > 3 months ago. • Age 18 to 90 years old.;Inclusion-criteria for the stroke patients without seizures or epilepsy: • History of stroke • No history of epileptic seizures or syncope of unknown origin. • Matched with patients of the first group on the following criteria: - age - gender - time since stroke - stroke severity or modified Rankin score at stroke onset - lacunar stroke vs. cortical stroke - presence of cardiac emboli source;Inclusion-criteria for the participants without stroke or epilepsy: - aged 18 years of older. - no history of stroke, epileptic seizures, degenerative brain disease or brraintumor.
Exclusion criteria
Exclusion criteria: Exclusion-criteria for all groups: • Not able or willing to provide informed consent. • Severe illness or cognitive decline preventing adequate investigations (including global aphasia) • The patient objects against the use of medical records and/or body materials for scientific investigations (as recorded in Mirador)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In the stroke group and the poststroke seizure group: • cognitive function: - the Mini-mental-state examination (MMSE) - information processing task (Fepsy: CVST) - either an auditive or visual reaction time task (Fepsy: auditive reaction task, Fepsy: visual reaction task) • quality of life: - EuroQol - stroke-adapted Sickness Impact Profile (SA-SIP-30) • disability: Barthel index • handicap: modified Rankin score • mood: depression and anxiety score (HADS) • stroke severity: National Institutes of Health Stroke Scale (NIHSS) • patient residence at present • side effects: SIDAED list In the poststroke seizure group: • seizure count • seizure severity: NHS3 • current AED treatment • history of AED treatment including considerations made by the clinician to switch AED treatment In all participants: • DNA testing for a polymorphism of the GRIN1 gene coding for the subunit NR1 of the NMDA receptor | — |
Secondary
| Measure | Time frame |
|---|---|
| No diversion between primary and secundary study parameters is made in this observational study. See for study parameters the previous section. | — |
Countries
Netherlands
Outcome results
None listed